AHCO
ACHAT TOTAL: 43 500 titres (~277 330,00 $ US)
- Insiders
- SAMET KENNETH A, WOLF DALE B
- Total bought
- $277,330
- Total sold
- —
- Last activity
- 2026-08-06
- Last synced
-
2026-08-12 09:47:22
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-09-06
AHCO presents a deeply unfavorable risk/reward profile: weak financial health (liquidity score 45, fundamentals trend 35) combined with a very low catalyst score (20) driven by insider buys that are directly…
The first sentence of the analysis written for AHCO on 2026-09-06 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 17.5% | 20.9% | 21.3% | 14.1% | 18.2% | |
| Ebit Margin | 2.8% | 8.1% | -18.5% | 7.0% | 11.7% | |
| Ebitda Margin | 15.5% | 19.3% | -5.3% | 21.2% | 22.2% | |
| Operating Profit Margin | 5.7% | 8.1% | -18.7% | 6.4% | 9.2% | |
| Pretax Profit Margin | -0.5% | 4.2% | -22.6% | 3.3% | 7.8% | |
| Continuous Operations Profit Margin | -2.0% | 2.9% | -21.1% | 2.5% | 6.4% | |
| Net Profit Margin | -2.2% | 2.8% | -21.2% | 2.3% | 6.4% | |
| Bottom Line Profit Margin | -2.2% | 2.5% | -22.3% | 2.1% | 3.6% | |
| Current Ratio | 1.023 | 1.333 | 1.209 | 1.283 | 1.341 | |
| Quick Ratio | 0.811 | 1.086 | 0.997 | 1.003 | 1.094 | |
| Solvency Ratio | 0.123 | 0.157 | -0.085 | 0.161 | 0.130 | |
| Cash Ratio | 0.149 | 0.194 | 0.144 | 0.101 | 0.299 | |
| Price To Earnings Ratio | -19.154 | 15.355 | -1.370 | 36.962 | 21.839 | |
| Price To Earnings Growth Ratio | 0.104 | -0.138 | 0.001 | -0.690 | -0.114 | |
| Forward Price To Earnings Growth Ratio | 0.104 | -0.138 | 0.001 | -0.690 | -0.114 | |
| Price To Earnings Diluted Ratio | -19.154 | 15.607 | -1.373 | 38.440 | 36.507 | |
| Price To Earnings Diluted Growth Ratio | 0.103 | -0.140 | 0.001 | -1.515 | -0.236 | |
| Price To Book Ratio | 0.886 | 0.810 | 0.671 | 1.199 | 1.498 | |
| Price To Sales Ratio | 0.415 | 0.390 | 0.306 | 0.868 | 1.259 | |
| Price To Free Cash Flow Ratio | 6.136 | 5.401 | 6.829 | -146.892 | 42.689 | |
| Price To Operating Cash Flow Ratio | 2.237 | 2.350 | 2.035 | 6.898 | 11.207 | |
| Debt To Assets Ratio | 0.441 | 0.475 | 0.509 | 0.446 | 0.452 | |
| Debt To Equity Ratio | 1.253 | 1.356 | 1.573 | 1.083 | 1.150 | |
| Debt To Capital Ratio | 0.556 | 0.576 | 0.611 | 0.520 | 0.535 | |
| Long Term Debt To Capital Ratio | 0.531 | 0.556 | 0.590 | 0.500 | 0.514 | |
| Financial Leverage Ratio | 2.843 | 2.856 | 3.091 | 2.426 | 2.546 | |
| Working Capital Turnover Ratio | 31.610 | 21.680 | 26.545 | 19.848 | 44.050 | |
| Operating Cash Flow Ratio | 0.845 | 0.956 | 0.895 | 0.819 | 0.552 | |
| Operating Cash Flow Sales Ratio | 0.185 | 0.166 | 0.150 | 0.126 | 0.112 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.365 | 0.435 | 0.298 | -0.047 | 0.263 | |
| Debt Service Coverage Ratio | 3.591 | 4.106 | -0.665 | 4.196 | 4.439 | |
| Interest Coverage Ratio | 1.761 | 2.082 | -4.593 | 1.740 | 2.370 | |
| Short Term Operating Cash Flow Coverage Ratio | 29.625 | 33.344 | 9.007 | 10.682 | 13.784 | |
| Operating Cash Flow Coverage Ratio | 0.316 | 0.254 | 0.209 | 0.161 | 0.116 | |
| Capital Expenditure Coverage Ratio | 1.574 | 1.770 | 1.424 | 0.955 | 1.356 | |
| Dividend Paid And Capex Coverage Ratio | 1.574 | 1.770 | 1.424 | 0.955 | 1.356 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 6.240 | 5.245 | -18.677 | 7.707 | 9.758 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 17.5% | ▼-3.4% | ▼-0.9% |
| Ebit Margin | 2.8% | ▼-5.3% | ▲0.6% |
| Ebitda Margin | 15.5% | ▼-3.7% | ▲0.9% |
| Operating Profit Margin | 5.7% | ▼-2.4% | ▲3.6% |
| Pretax Profit Margin | -0.5% | ▼-4.6% | ▲1.1% |
| Continuous Operations Profit Margin | -2.0% | ▼-4.9% | ▲0.2% |
| Net Profit Margin | -2.2% | ▼-5.0% | ▲0.2% |
| Bottom Line Profit Margin | -2.2% | ▼-4.7% | ▲1.1% |
| Current Ratio | 1.023 | ▼-0.310 | ▼-0.214 |
| Quick Ratio | 0.811 | ▼-0.276 | ▼-0.187 |
| Solvency Ratio | 0.123 | ▼-0.034 | ▲0.026 |
| Cash Ratio | 0.149 | ▼-0.045 | ▼-0.028 |
| Price To Earnings Ratio | -19.154 | ▼-34.509 | ▼-29.880 |
| Price To Earnings Growth Ratio | 0.104 | ▲0.242 | ▲0.271 |
| Forward Price To Earnings Growth Ratio | 0.104 | ▲0.242 | ▲0.271 |
| Price To Earnings Diluted Ratio | -19.154 | ▼-34.760 | ▼-33.159 |
| Price To Earnings Diluted Growth Ratio | 0.103 | ▲0.243 | ▲0.461 |
| Price To Book Ratio | 0.886 | ▲0.076 | ▼-0.127 |
| Price To Sales Ratio | 0.415 | ▲0.024 | ▼-0.233 |
| Price To Free Cash Flow Ratio | 6.136 | ▲0.735 | ▲23.303 |
| Price To Operating Cash Flow Ratio | 2.237 | ▼-0.113 | ▼-2.708 |
| Debt To Assets Ratio | 0.441 | ▼-0.034 | ▼-0.024 |
| Debt To Equity Ratio | 1.253 | ▼-0.103 | ▼-0.030 |
| Debt To Capital Ratio | 0.556 | ▼-0.019 | ▼-0.003 |
| Long Term Debt To Capital Ratio | 0.530 | ▼-0.025 | ▼-0.007 |
| Financial Leverage Ratio | 2.842 | ▼-0.013 | ▲0.090 |
| Working Capital Turnover Ratio | 31.610 | ▲9.929 | ▲2.863 |
| Operating Cash Flow Ratio | 0.845 | ▼-0.111 | ▲0.031 |
| Operating Cash Flow Sales Ratio | 0.185 | ▲0.019 | ▲0.037 |
| Free Cash Flow Operating Cash Flow Ratio | 0.365 | ▼-0.071 | ▲0.102 |
| Debt Service Coverage Ratio | 3.591 | ▼-0.514 | ▲0.458 |
| Interest Coverage Ratio | 1.761 | ▼-0.321 | ▲1.089 |
| Short Term Operating Cash Flow Coverage Ratio | 29.625 | ▼-3.719 | ▲10.337 |
| Operating Cash Flow Coverage Ratio | 0.316 | ▲0.062 | ▲0.105 |
| Capital Expenditure Coverage Ratio | 1.574 | ▼-0.197 | ▲0.158 |
| Dividend Paid And Capex Coverage Ratio | 1.574 | ▼-0.197 | ▲0.158 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 6.240 | ▲0.995 | ▲4.185 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $1.35B | $1.27B | $978.0M | $2.58B | $3.09B | |
| Enterprise value | $3.14B | $3.29B | $3.20B | $4.86B | $5.31B | |
| EV / Sales | 0.97x | 1.01x | 1.00x | 1.64x | 2.16x | |
| EV / Op. cash flow | 5.22x | 6.08x | 6.65x | 13.00x | 19.26x | |
| EV / Free cash flow | 14.32x | 13.97x | 22.32x | -276.91x | 73.38x | |
| EV / EBITDA | 6.24x | 5.25x | -18.68x | 7.71x | 9.76x | |
| Net debt / EBITDA | 3.57x | 3.22x | -12.96x | 3.62x | 4.08x | |
| Current ratio | 1.02x | 1.33x | 1.21x | 1.28x | 1.34x | |
| Income quality | -9.11x | 5.72x | -0.71x | 5.11x | 1.74x | |
| Graham number | — | $13 | — | $14 | $21 | |
| Graham net-net | -$17 | -$18 | -$20 | -$20 | -$21 | |
| Tax burden | 467.2% | 66.5% | 93.8% | 70.8% | 81.8% | |
| Interest burden | -16.7% | 51.8% | 122.3% | 47.2% | 66.7% | |
| Working capital | $16.5M | $188.8M | $112.0M | $129.1M | $170.2M | |
| Invested capital | $3.32B | $3.59B | $3.60B | $4.46B | $4.43B | |
| Return on assets | -1.6% | 2.0% | -15.1% | 1.3% | 3.0% | |
| Operating ROA | 4.2% | 5.9% | -12.3% | 3.6% | 6.4% | |
| Return on tangible assets | -4.2% | 5.3% | -41.1% | 4.6% | 10.2% | |
| Return on equity | -4.7% | 5.8% | -46.5% | 3.2% | 7.6% | |
| Return on invested capital | 5.1% | 4.6% | -13.7% | 2.9% | 3.9% | |
| Return on capital employed | 5.2% | 6.7% | -15.1% | 4.0% | 4.7% | |
| Earnings yield | -5.3% | 7.1% | -69.4% | 2.7% | 5.1% | |
| Free cash flow yield | 16.3% | 18.5% | 14.6% | -0.7% | 2.3% | |
| Capex / Op. cash flow | 63.5% | 56.5% | 70.2% | 104.7% | 73.7% | |
| Capex / Depreciation | 100.1% | 83.8% | 80.2% | 111.5% | 78.8% | |
| Capex / Sales | 11.8% | 9.4% | 10.5% | 13.2% | 8.3% | |
| SG&A / Sales | 11.8% | 11.0% | 5.9% | 5.5% | 6.8% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.7% | 0.5% | 0.7% | 0.8% | 1.0% | |
| Intangibles / Total assets | 60.8% | 62.0% | 63.3% | 71.0% | 70.8% | |
| Days sales outstanding | 42d | 46d | 44d | 44d | 54d | |
| Days payables outstanding | 48d | 40d | 31d | 32d | 45d | |
| Operating cycle | 62d | 65d | 61d | 62d | 76d | |
| Cash conversion cycle | 14d | 25d | 30d | 31d | 31d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+5.7%EV / Sales ▼-4.1%EV / EBITDA ▲+19.0%EV / Op. cash flow ▼-0.857Earnings yield ▼-0.124
Profitability
Return on equity ▼-0.104Return on assets ▼-0.037Return on invested capital ▲+0.005Return on capital employed ▼-0.016Operating ROA ▼-0.016Income quality ▼-14.829Tax burden ▲+4.007
Efficiency
Days sales outstanding ▼-3.949Days payables outstanding ▲+7.793Operating cycle ▼-3.106Cash conversion cycle ▼-10.899Capex / Sales ▲+0.024R&D / Sales n/a
Balance-sheet strength
Current ratio ▼-0.310Net debt / EBITDA ▲+0.350Working capital ▼-172294000.000Invested capital ▼-270591000.000Intangibles / Total assets ▼-0.011
Change over 5 years
Valuation
Market cap ▼-56.4%EV / Sales ▼-55.2%EV / EBITDA ▼-36.1%EV / Op. cash flow ▼-14.041Earnings yield ▼-0.103
Profitability
Return on equity ▼-0.122Return on assets ▼-0.046Return on invested capital ▲+0.012Return on capital employed ▲+0.004Operating ROA ▼-0.022Income quality ▼-10.856Tax burden ▲+3.854
Efficiency
Days sales outstanding ▼-11.797Days payables outstanding ▲+2.995Operating cycle ▼-13.535Cash conversion cycle ▼-16.530Capex / Sales ▲+0.035R&D / Sales n/a
Balance-sheet strength
Current ratio ▼-0.317Net debt / EBITDA ▼-0.514Working capital ▼-153739000.000Invested capital ▼-1114101000.000Intangibles / Total assets ▼-0.099
Employee count
Peer market caps
Congressional trades
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2022-11-30 | Susie Lee | Sale (Full) | $1,001 - $15,000 |
| 2022-04-22 | Kevin Hern | Sale (Full) | $1,001 - $15,000 |
| 2022-04-01 | Kevin Hern | Sale (Full) | $50,001 - $100,000 |
| 2021-05-26 | Susie Lee | Purchase | $1,001 - $15,000 |
| 2021-05-20 | Kevin Hern | Purchase | $1,001 - $15,000 |
| 2021-02-11 | Susie Lee | Purchase | $1,001 - $15,000 |
| 2021-02-09 | Susie Lee | Purchase | $1,001 - $15,000 |
| 2021-01-22 | Susie Lee | Purchase | $1,001 - $15,000 |
| 2021-01-05 | Susie Lee | Purchase | $1,001 - $15,000 |
Recent news
- 2026-08-11 AdaptHealth Sells Diabetes Unit to Sharpen Focus on Sleep, Respiratory Growth AdaptHealth NASDAQ: AHCO executives outlined the company''s second-quarter performance, portfolio changes and plans to focus capital on sleep, respiratory and home medical equipment businesses during a Canaccord conference discussion.
- 2026-08-09 Why AdaptHealth Stock Plummeted This Week AdaptHealth posted a huge earnings miss in Q2, and sales also came in below expectations. The company also lowered its fiscal performance targets for the year.
- 2026-08-08 AHCO Investors Have Opportunity to Join AdaptHealth Corp. Fraud Investigation with SBS Law [url="]Schall, Brown and Schwartz[/url] LLP (âSBSâ), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of inv
- 2026-08-08 AHCO Investors Have Opportunity to Join AdaptHealth Corp. Fraud Investigation with SBS Law LOS ANGELES--(BUSINESS WIRE)---- $AHCO--AHCO Investors Have Opportunity to Join AdaptHealth Corp. Fraud Investigation with SBS Law.
- 2026-08-07 AdaptHealth Corp. to Participate in Upcoming Investor Conferences CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, announced today that they will participate in the following upcoming investor conferences: The Canaccord Genuity 46th Annual Growth Conference, being held in Boston, on Tuesday, August 11, 2026, including a fireside chat from 9:00 – 9:25 a.m. E.
- 2026-08-07 AHCO Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into AdaptHealth Corp. (AHCO) NEW YORK--(BUSINESS WIRE)--AdaptHealth Corp. (NASDAQ: AHCO) shares fell as much as 26% after the Company reported second quarter revenue of $740.3 million, well below approximately $847 million expected, a GAAP loss driven in part by a $144.2 million goodwill impairment charge, and a substantial reduction to full-year guidance. If you suffered a loss on your AdaptHealth investment, you are encouraged to click here to submit your information. You may also contact Joseph E. Levi, Esq. via email a.
- 2026-08-06 Securities Fraud Investigation Into AdaptHealth Corp. (AHCO) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of AdaptHealth Corp. (“AdaptHealth” or the “Company”) (NASDAQ: AHCO) investors concerning the Company''s possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON ADAPTHEALTH CORP. (AHCO), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What Happened? O.
- 2026-08-06 AdaptHealth Corp. (AHCO) Shareholders Who Lost Money -- Contact Law Offices of Howard G. Smith About Securities Fraud Investigation Law Offices of Howard G. Smith announces an investigation on behalf of AdaptHealth Corp. (âAdaptHealthâ or the âCompanyâ) (NASDAQ: [url="]AHCO[/url]) in
- 2026-08-06 AdaptHealth Corp. (AHCO) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of AdaptHealth Corp. (“AdaptHealth” or the “Company”) (NASDAQ: AHCO) investors concerning the Company''s possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN ADAPTHEALTH CORP. (AHCO), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your legal rights by e.
- 2026-08-06 AdaptHealth Q2 Earnings Call Highlights AdaptHealth (NASDAQ: AHCO) reported second-quarter revenue growth in its continuing operations but lowered its full-year profitability outlook, citing higher-than-expected costs in its West Coast capitated contract, a supplier price increase and portfolio actions. Chief Executive Officer Suzanne Foster said the company delivered 15.9% organic revenue growth during the quarter, supported by record volume gains. Continuing-operations net